We previously proposed that therapeutically elevating neurofibromin activity in NF1 haploinsufficient Schwann cell environments will slow or reverse tumor development and other NF1 manifestations.17 One way to identify treatments that therapeutically elevate neurofibromin is to screen many drugs that cause the desired effect. This evidence concerns the gene NF1 and neoplasm.